This can be attributed to the development of enzalutamide resistance in prostate cancer due to several factors such as the emergence of AR splice variants [18, 19], glucocorticoid receptor expression [20], AR F876L domain mutation [21], and neuroendocrine differentiation [22], etc. In the face of the current situation of drug resistance caused by multiple factors, the drug’s limited therapeutic effect and the drug resistance lethality are becoming clinical challenges that need to be resolved. This evidence concerns the gene AR and prostate cancer.